期刊
ANNALS OF SURGICAL ONCOLOGY
卷 29, 期 5, 页码 2735-2738出版社
SPRINGER
DOI: 10.1245/s10434-021-11276-4
关键词
-
This article reviews the findings of a randomized clinical trial evaluating adjuvant nivolumab in esophageal or gastroesophageal junction carcinoma. The study suggests that postoperative immunotherapy represents a significant treatment option for these aggressive malignancies.
This ASO perspective reviews the findings of a randomized placebo-controlled, clinical trial evaluating adjuvant nivolumab in esophageal or gastroesophageal junction carcinoma, reported recently by the Checkmate 577 investigators. The use of postoperative immunotherapy represents a significant paradigm shift for managing patients who have had limited evidence-based treatment options after completing neoadjuvant chemoradiation followed by resection for these aggressive malignancies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据